Table 2.

Comparison of trends in renal function in 30 Pima Indian participants with type 2 diabetes and elevated GFR at baseline^a

Method of GFR Estimation	Mean Baseline Value	Annual Percentage Change ± SD	Mean Difference ± SD	P Valueb
Total cohort (n = 30)
direct
iothalamate clearance (ml/min per 1.73 m2)	153 ± 27	−4.4 ± 10.3%
indirect
100/cystatin Cc	158 ± 34	−4.3 ± 7.4%	−0.1 ± 4.0%	0.88
100/creatininec	149 ± 37	−2.2 ± 8.6%	−2.2 ± 5.6%	0.09
Cockroft-Gault (ml/min)	167 ± 60	−3.4 ± 8.4%	−1.0 ± 6.1%	0.50
MDRD (ml/min per 1.73 m2)	130 ± 32	−2.8 ± 10.3%	−1.6 ± 7.9%	0.29
Declining renal functiond (n = 20)
direct
iothalamate clearance (ml/min per 1.73 m2)	156 ± 30	−8.1 ± 10.9%
indirect
100/cystatin Cc	163 ± 34	−6.9 ± 7.7%	−1.2 ± 4.1%	0.21
100/creatininec	148 ± 42	−3.8 ± 9.5%	−4.3 ± 7.1%	0.01
Cockroft-Gault (ml/min)	166 ± 66	−4.5 ± 9.5%	−3.6 ± 7.5%	0.04
MDRD (ml/min per 1.73 m2)	127 ± 35	−4.4 ± 11.2%	−3.7 ± 7.9%	0.07
Stable renal function (n = 10)
direct
iothalamate clearance (ml/min per 1.73 m2)	148 ± 18	2.9 ± 2.0%
indirect
100/cystatin Cc	149 ± 34	0.8 ± 2.8%	2.1 ± 3.0%	0.06
100/creatininec	153 ± 25	1.1 ± 5.3%	1.8 ± 5.2%	0.29
Cockroft-Gault (ml/min)	171 ± 48	−1.4 ± 5.4%	4.3 ± 5.1%	0.03
MDRD (ml/min per 1.73 m2)	137 ± 21	0.7 ± 7.1%	2.2 ± 6.7%	0.30

^aGFR >120 ml/min per 1.73 m² as determined by iothalamate clearance standardized for BSA.

^bPaired t test statistic.

^cArbitrary units.

^dDefined as a negative annual change in GFR as determined by iothalamate clearance standardized for BSA.